REVIVA PHARMACEUTICALS HOLDINGS, INC.

Reviva Pharmaceuticals Holdings, Inc., trading under the ticker TZAC, is a clinical-stage biopharmaceutical company operating in the healthcare and life sciences sector. The company filed an 8-K current report with the SEC on May 13, 2026, under accession number 0001437749-26-016760, disclosing a material event subject to reporting requirements. Reviva Pharmaceuticals, which focuses on treatments for central nervous system and metabolic disorders, reached its current public status through a SPAC business combination. The May 2026 filing reflects the company's ongoing disclosure obligations as a post-combination public entity. Visit SpacDesk and sign up for full access to TZAC filings, deal history, and sponsor data across the entire SPAC universe.